108975-09-3 Usage
Uses
Used in Pharmaceutical Industry:
(6-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid ethyl ester is used as an intermediate in the production of pharmaceuticals for its potential role in drug development. The chemical structure of this ester derivative allows for further modification and synthesis of new compounds with potential therapeutic properties.
Used in Chemical Research:
In the field of chemical research, (6-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid ethyl ester serves as a valuable compound for studying its reactivity, stability, and interactions with other molecules. This research can lead to a better understanding of its properties and potential applications in various chemical processes.
Used in Drug Discovery:
(6-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid ethyl ester is used as a candidate in drug discovery due to its potential biological activities and therapeutic properties. Further investigation in medicinal chemistry can reveal its effectiveness in treating specific diseases or conditions, making it a promising compound for future pharmaceutical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 108975-09-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,8,9,7 and 5 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 108975-09:
(8*1)+(7*0)+(6*8)+(5*9)+(4*7)+(3*5)+(2*0)+(1*9)=153
153 % 10 = 3
So 108975-09-3 is a valid CAS Registry Number.
108975-09-3Relevant academic research and scientific papers
ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF
-
Page/Page column 75, (2010/05/13)
Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
Bicyclic antagonists selective for the αvβ3 integrin
-
, (2008/06/13)
This invention provides novel bicyclic compounds of Formula (I): wherein u, v, m, Y, G, A—B, R1, R1a, R2, R4, R5, R5a, and R5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption and compounds of Formula (II) wherein u, v, m, Y, G, D, A—B, R1, R1a, R2, R3, R4, R5, R5a, and R5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption.
